NVAX - ノババックス （Novavax Inc.） ノババックスNVAXのチャート
NVAXの企業情報
| symbol | NVAx |
|---|---|
| 会社名 | Novavax Inc. （ノババックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ノババックス(Novavax Inc.)は臨床段階のバイオ医薬品会社である。同社は組換えナノ粒子ワクチン及びアジュバントの発見・開発・商業化に焦点を当てる。同社は組換えワクチンセグメントの開発を通じて事業を行っている。同社は、組換えナノ粒子ワクチン技術を用いて、既知疾患及び新興疾患に対応するワクチン候補物質を製造する。同社の製品パイプラインは、呼吸器合胞体ウイルス（RSV）、季節性インフルエンザ、パンデミックインフルエンザおよびエボラウイルス（EBOV）の臨床開発におけるワクチン候補の感染症に焦点を当てる。同社の人用鉛アジュバントであるMatrix-Mは、パンデミックインフルエンザH7N9ワクチン候補のフェーズI / II臨床試験にある。また、第I相臨床試験でEBOVワクチン候補と併せてMatrix-Mを試験している。同社は中東呼吸器症候群（MERS）を含む感染性疾患で、前臨床段階の追加プログラムを開発している。 ノババックスは、臨床段階の米国バイオ医薬品企業。組換えナノ粒子ワクチンおよび抗原性補強剤の発見、開発、商業化に従事する。呼吸器合胞体ウイルス、季節性インフルエンザと新型インフルエンザのための臨床開発などの感染症に対象を当て遺伝子組み換えによるワクチンを開発する。 Novavax, Inc. is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. |
| 本社所在地 | 20 Firstfield Road Garthersburg MD 20878 USA |
| 代表者氏名 | James Francis Young ジェームズ・フランシス・ヤング |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 240-268-2000 |
| 設立年月日 | 1987年 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 347人 |
| url | www.novavax.com |
| nasdaq_url | https://www.nasdaq.com/symbol/nvax |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -165.13200 |
| 終値（lastsale） | 2.065 |
| 時価総額（marketcap） | 790052064.935 |
| 時価総額 | 時価総額（百万ドル） 723.09850 |
| 売上高 | 売上高（百万ドル） 39.19000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 874.46250 |
| 当期純利益 | 当期純利益（百万ドル） -186.29300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Novavax Inc. revenues increased 65% to $20.4M. Net loss increased 3% to $90.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase of 16% to $83.5M (expense) Labor_Related Expenses in R&D increase of 18% to $5.6M (expense). |
NVAXのテクニカル分析
NVAXのニュース
Novavax to Host Conference Call to Discuss First Quarter 2023 Financial Results and Operational Highlights on May 9, 2023 2023/05/02 13:25:00 PR Newswire
GAITHERSBURG, Md., May 2, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M adjuvant, today announced it will report its first quarter 2023 financial results and operational highlights at 8:30 a.m. EDT on Tuesday,…
Novavax: Dead Cat Bounce 2023/04/26 18:57:46 Seeking Alpha
Novavax bounced on hype while the prospects from the business continue to dim with the demand for Covid vaccines. Click here for our take on VNAX stock.
Friday’s Top Analyst Upgrades and Downgrades: Alphabet, Citizens Financial, Emerson Electric, GE, Las Vega Sands, Medical Properties Trust, Microsoft, Nio, Tesla and More 2023/04/21 12:57:25 24/7 Wall street
Friday''s top analyst upgrades and downgrades included Alphabet, Chegg, Citizens Financial, Comstock Resources, Coterra Energy, CubeSmart, Emerson Electric, Fastly, General Electric, Las Vega Sands, Medical Properties Trust, Microsoft, Nio, Novavax, Raytheon Technologies, Sea, Tesla, Tripadvisor, Ventas, Welltower and WestRock.
Novavax Dives On Downgrade; Is It The Covid Engine That Couldn’t? 2023/04/20 20:10:03 ReportWire
Novavax (NVAX) has a solid platform but continues to face a $700…
7 Short-Squeeze Stocks That Are Breaking All the Rules 2023/04/20 17:22:14 InvestorPlace
Thanks to social media platforms, retail investors learned firsthand the power of short-squeeze stocks. Essentially, through coordinated action, it’s possible to overwhelm securities featuring heavy bearish sentiment. Subsequently, rising prices of the affected securities may cause bears to panic out of their positions to avoid theoretically unlimited losses . However, a flipside to this narrative exists. Primarily, the existence of short-squeeze stocks symbolizes a bearish framework, not a bullish one. In other words, a negative catalyst had to materialize to inspire short traders. Because of the huge risks involved in shorting an enterprise, a business that attracts so much pessimism must be awful. Second, the purpose of bidding up short-squeeze stocks centers on overlooked bullish fundamentals. However, more than a few bearish trades show little to no apparent redeeming factors, yet they continue to attract speculators. That’s frustrating, to say the least. Below are seven companies that break the rules regarding short trades.
Novavax Inc. (NASDAQ: NVAX): It Is A Stock Worth Considering Today 2022/10/03 13:30:00 Marketing Sentinel
In the last trading session, 3.75 million shares of the Novavax Inc. (NASDAQ:NVAX) were traded, and its beta was 1.85. Most recently the company’s share price was $18.20, and it changed around -$0.37 or -1.99% from the last close, which brings the market valuation of the company to $1.45B. NVAX currently trades at a discount … Novavax Inc. (NASDAQ: NVAX): It Is A Stock Worth Considering Today Read More »
Codexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors 2022/10/03 12:00:00 Benzinga
REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS ), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors. Dr. Singhvi is a biotechnology industry veteran with more than three decades of research and development, operations and commercialization expertise across his time with Takeda Pharmaceutical Co., Novavax, Inc. and Merck & Co., Inc. He currently serves as the Chief Executive Officer of National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company, which he co-founded and built, with end-to-end manufacturing and digital solutions across several modalities including cell and gene therapies, nucleic acids, vaccines and biologics. "Rahul is a proven leader in the biopharmaceutical industry, with a demonstrated track record of enabling scale and accelerating the growth of innovative product pipelines," said Byron Dorgan, Chair of the Board of Codexis. "His insights and guidance across drug development and driving adoption of boundary-pushing technologies will prove invaluable throughout Codexis'' evolution, and we are fortunate to welcome him to …
Novavax Stock: Beware This Hypercoaster (NASDAQ:NVAX) 2022/09/30 05:23:41 Seeking Alpha
Novavax is the hypercoaster of stocks having crested $300 in 02/22, falling to <$130 and then doubling and then crashing. See why NVAX is a tricky holding.
MRNA stock, NVAX stock, OCGN stock plunge (NASDAQ:MRNA) 2022/09/29 14:47:19 Seeking Alpha
The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (MRNA) and Novavax (NVAX) reaching 52-week lows.Its rivals in COVID-19 vaccine…
Novavax, Siegfried extend COVID-19 vaccine production deal (NASDAQ:NVAX) 2022/09/28 16:59:22 Seeking Alpha
Swiss life sciences company Siegfried Holding AG (SGFEF) announced Wednesday that it decided to extend the collaboration with Novavax (NVAX) for the fill & finish process of the U.S
Novavax: Down but Far From Out, Says Analyst 2022/09/02 18:26:45 TipRanks
After various setbacks, Novavax (NVAX) finally managed to get its Covid-19 vaccine across the finish line this year. That has done little, however, to alter the sto…
How to get the omicron COVID-19 booster shot 2022/09/02 18:26:44 Deseret
A syringe is checked prior to a booster vaccine by a Nomi Health worker in West Valley City on July 14, 2022. Jeffrey D. Allred, Deseret News The new omicron-targeted COVID-19 booster shots may be shipping Friday, but aren’t expected to be widely available until after the Labor Day holiday. The first updated COVID-19 booster doses — also known as “bivalent vaccines” — from Pfizer and Moderna won quick approval this week from the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention to be ready for another potential COVID-19 surge this fall. Related Forget herd immunity. Best case may be ‘herd safety,’ new COVID-19 study suggests Here’s what you need to know: Who can get an omicron booster shot? Teens and adults who have been fully vaccinated for at least two months. Fully vaccinated means having received the first two doses of the original Pfizer or Moderna vaccine, or the recently approved Novavax vaccine , or the single dose of the Johnson & Johnson vaccine that’s no longer recommended for most people Teens and adults who have waited at least two months since their most recent booster shot Pfizer’s omicron booster is authorized for people 12 and older Modern’s omicron booster is authorized for people 18 and older Related Will Novavax be the ‘perfect option’ for those still unvaccinated against COVID-19?
Novavax, Inc.: Swissmedic Authorizes Novavax Nuvaxovid COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Adults Aged 18 and Older 2022/09/02 18:10:00 Finanz Nachrichten
GAITHERSBURG, Md., Sept. 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious d…
Swissmedic Authorizes Novavax Nuvaxovid COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Adults Aged 18 and Older 2022/09/02 18:07:00 Wallstreet:Online
GAITHERSBURG, Md., Sept. 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has expanded its temporary authorization of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in Switzerland for
Novavax Inc. (NASDAQ:NVAX) Currently -769.48% Below Its 52-Week High, But There May Be A Surprise Downside 2022/09/02 14:00:00 Marketing Sentinel
In last trading session, Novavax Inc. (NASDAQ:NVAX) saw 4.73 million shares changing hands with its beta currently measuring 1.48. Company’s recent per share price level of $31.95 trading at -$1.09 or -3.30% at ring of the bell on the day assigns it a market valuation of $2.64B. That closing price of NVAX’s stock is at … Novavax Inc. (NASDAQ:NVAX) Currently -769.48% Below Its 52-Week High, But There May Be A Surprise Downside Read More »